Rainbow Childrens Medicare Limited has confirmed that its promoters and promoter group did not encumber any shares held directly or indirectly during the financial year ended March 31, 2026. This disclosure ensures that the shareholding structure remains free from pledged assets, providing stability to the company's ownership base. The declaration was submitted to the National Stock Exchange of India Limited and BSE Limited in compliance with regulatory requirements.

Dr. Ramesh Kancharla, Promoter of rainbow childrens medicare , made the declaration on behalf of the promoters and promoter group pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The regulation mandates such disclosures to maintain transparency regarding the holding patterns of key stakeholders.

The declaration covers seven entities and individuals associated with the company. The list includes individual promoters as well as members of the promoter group, which includes specific family trusts. The confirmation of no encumbrance applies to all listed entities acting in concert with the promoters.

Details of Promoters and Promoter Group

The filing was addressed to the Corporate Relationship Department of BSE Limited and the Exchange Plaza of the National Stock Exchange of India Limited. A copy of the declaration has also been forwarded to the Audit Committee of Rainbow Childrens Medicare Limited for record-keeping purposes.

[Rainbow Children's Medicare Limited](rainbow childrens medicare) has reported a 15.3% increase in consolidated net profit to ₹2,815.44 million for the financial year ended March 31, 2026, compared to ₹2,442.27 million in the previous year. Revenue from operations for the year rose 12.4% to ₹17,030.77 million from ₹15,158.66 million in FY25. The board of directors, in its meeting held on May 23, 2026, approved the audited standalone and consolidated financial results and recommended a final dividend of ₹3.5 per equity share. The company’s strong performance was driven by healthy momentum across operating metrics, including outpatient footfalls, inpatient discharges, and deliveries, alongside the successful commissioning of new facilities in Bengaluru.

Financial Performance

The company’s profitability improved alongside revenue growth. For the full year, total income reached ₹17,468.65 million, while total expenses stood at ₹13,870.97 million. Profit before tax for the year was ₹3,582.29 million. On a standalone basis, net profit for FY26 was ₹2,500.16 million, with revenue from operations reaching ₹15,456.60 million. EBITDA for the year rose 11.1% to ₹5,442 million, with an EBITDA margin of 32.0%.

The following table summarizes the key consolidated financial figures for the full year:

Q4 Performance

In the quarter ended March 31, 2026, consolidated net profit stood at ₹782.18 million, a 38.3% increase from ₹565.53 million in the same quarter of the previous year. Revenue from operations reached ₹4,599.01 million, compared to ₹3,701.07 million year-on-year. EBITDA for the quarter rose 26.1% to ₹1,447 million, with the EBITDA margin expanding to 31.5% from 31.0%. On a standalone basis, net profit for the quarter was ₹593.05 million on revenue of ₹4,080.64 million.

Operational Highlights

The company maintained robust operational metrics during the year. Capacity beds increased 23% to 2,375, while operational beds grew 10% to 1,677. Occupancy for the year stood at 46.26%. Inpatient discharges rose 6% to 104,514, and outpatient consultations increased 12% to 15,98,970. Deliveries for the year reached 19,228. The Average Revenue Per Occupied Bed (ARPOB) improved 11% to ₹60,141, while the Average Length of Stay (ALOS) decreased to 2.71 days from 2.85 days in the previous year.

Dividend and Appointments

The board has recommended a final dividend of ₹3.5 per equity share, representing 35% on a face value of ₹10 per share for FY26. The total dividend payout aggregates to ₹355.46 million. The record date for determining eligibility has been fixed as July 21, 2026, and the payment is subject to shareholder approval at the 28th Annual General Meeting scheduled for July 29, 2026.

The board approved the re-appointment of Dr. Ramesh Kancharla as Chairman and Managing Director and Dr. Dinesh Kumar Chirla as Whole Time Director for a period of five years from August 11, 2026. Additionally, Mr. Santanu Mukherjee and Ms. Sundari R. Pisupati were re-appointed as Independent Directors for second terms of five years each. M/s. Lavanya & Associates LLP were re-appointed as Cost Auditors for FY27.

Investor Conference Call

Pursuant to Regulation 30 and 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, the audio recording of the conference call held on May 25, 2026, with investors and analysts to discuss the financial and operational performance for Q4 and FY26 is now available on the company's website.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE961O01016/765b96f7-e995-470a-8cee-a3fbf38a46af.pdf